Latest Oligodendroglioma Stories

First ever medical device therapy indicated as an alternative to chemotherapy for cancerNovocure today announced that the U.S. Food and Drug Administration (FDA) approved the NovoTTF-100A System (NovoTTF) for the treatment of adult patients with glioblastoma multiforme (GBM) brain tumors, following tumor recurrence after receiving chemotherapy. The portable, wearable device delivers an anti-mitotic, anti-cancer therapy as patients maintain their normal daily activities. The NovoTTF is a...

St. Jude Children's Research Hospital investigators use a novel model system to show how specific mutations can induce glioma formation in multiple regions of the brain and to begin studying patient response to a new generation of targeted therapiesMutations in three pathways important for suppressing tumors cooperate to launch glioblastoma, an aggressive brain tumor that strikes children and adults. But new research from St. Jude Children's Research Hospital scientists shows those changes...

Scientists at Duke Cancer Institute have discovered that genetic mutations found in brain tumors can alter tumor metabolism. This work could help lead to new designs for anti-cancer drugs based on the unique properties of these tumors."Malignant glioma appears to be at least two large subclasses of diseases "“ one that involves mutations in the IDH1 and IDH2 genes and one that doesn't," said Hai Yan, M.D., Ph.D., an associate professor in the Duke Department of Pathology who led a...

Scientists have identified the type of cell that is at the origin of brain tumors known as oligodendrogliomas, which are a type of glioma "“ a category that defines the most common type of malignant brain tumor.In a paper published in the December 2010 issue of the journal Cancer Cell, investigators found that the tumor originates in and spreads through cells known as glial progenitor cells "“ cells that are often referred to as "daughter" cells of stem cells. The work comes at a time...

New research shows that loss of a gene called NFKBIA promotes the growth of glioblastoma multiforme, the most common and deadly form of brain cancer, and suggests that therapies that stabilize this gene may improve survival for certain glioblastoma patients.The study was published recently in the New England Journal of Medicine."We show that NFKBIA status may be an independent predictor of survival in certain patients with glioblastoma," says senior coauthor Dr. Arnab Chakravarti, chair and...

(Ivanhoe Newswire) -- The deletion of a gene called NFKBIA may cause glioblastoma, the most common and malignant brain cancer. Researchers at the Stanford University School of Medicine recently discovered that the deletion of this gene, which is known to promote tumor development and resistance to therapy, was present in one out of every four glioblastoma cases.When NFKBIA is deleted, certain biochemical processes occur with striking similarity to an onset of glioblastoma, which often results...

A study fast-tracked for online publication Dec. 22 in the New England Journal of Medicine has identified an important gene deletion in up to one of every four cases of glioblastoma, the most common adult brain cancer. This deletion contributes to tumor development, promotes resistance to therapy and considerably worsens a patient's survival prospects.The deletion of the gene, known as NFKBIA, triggers biochemical processes similar to those resulting from a better-known aberration common in...

For patients with glioma, the most common primary brain tumor, new findings may explain why current therapies fail to eradicate the cancer.  A UCSF-led team of scientists has identified for the first time that progenitor rather than neural stem cells underly a type of glioma called oligodendroglioma.  This distinction explains why oligodendroglioma is more responsive to therapy than other brain tumors such as glioblastoma multiforme.The finding is significant, the researchers say,...

Data presented today from a pivotal, phase III randomized clinical trial for patients with recurrent glioblastoma tumors suggest that Tumor Treating Fields (TTF) therapy may increase median survival time and improve quality of life scores compared to best standard of care chemotherapy. Professor Zvi Ram, chairman of the Department of Neurosurgery at Tel-Aviv Sourasky Medical Center, presented the data at the Society for Neuro-Oncology (SNO) Annual Scientific Meeting.Physicians delivered the...

MONTREAL, Nov. 19, 2010 /PRNewswire/ -- Data presented today from a pivotal, phase III randomized clinical trial for patients with recurrent glioblastoma tumors suggest that Tumor Treating Fields (TTF) therapy may increase median survival time and improve quality of life scores compared to best standard of care chemotherapy. Professor Zvi Ram, chairman of the Department of Neurosurgery at Tel-Aviv Sourasky Medical Center, presented the data at the Society for Neuro-Oncology (SNO) Annual...